Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1984 Mar;55(3):519–524.

Long term administration of cyclophosphamide into MRL/1 mice. II. The effects on the isotype of anti-DNA antibodies and immunoglobulin secreting cells in the spleen.

M Shiraki, M Fujiwara
PMCID: PMC1535928  PMID: 6608425

Abstract

Weekly injections of cyclophosphamide (Cy) at a dose of 20 mg/kg body weight prevented IgM to IgG class switch of serum anti-DNA antibodies and also immunoglobulin secreting cells in the spleen of MRL/Mp-lpr/lpr (MRL/1) mice. Culture experiments revealed that splenic B cells of Cy treated mice gave rise to more IgM and less IgG secreting cells than those of untreated mice in response to lipopolysaccharide. These results suggested that Cy suppressed enhanced differentiation of B cells into IgG secreting cells in MRL/1 mice, which would result in reduction of IgG anti-single stranded DNA antibodies and improvement of murine lupus like syndrome.

Full text

PDF
519

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fujiwara M., Akiyama Y. LPS-induced autoantibody response. I. Ontogenic development of PFC response to bromelain-treated syngeneic erythrocytes. Cell Immunol. 1980 Oct;55(2):366–380. doi: 10.1016/0008-8749(80)90168-9. [DOI] [PubMed] [Google Scholar]
  2. Goodman M. G., Weigle W. O. T cell regulation of polyclonal B cell responsiveness. I. Helper effects of T cells. J Immunol. 1979 Jun;122(6):2548–2553. [PubMed] [Google Scholar]
  3. Gronowicz E., Coutinho A., Melchers F. A plaque assay for all cells secreting Ig of a given type or class. Eur J Immunol. 1976 Aug;6(8):588–590. doi: 10.1002/eji.1830060812. [DOI] [PubMed] [Google Scholar]
  4. Julius M. H., Simpson E., Herzenberg L. A. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973 Oct;3(10):645–649. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  5. Koffler D., Agnello V., Carr R. I., Kunkel H. G. Anti-DNA antibodies and renal lesions of patients with systemic lupus erythematosus. Transplant Proc. 1969 Dec;1(4):933–938. [PubMed] [Google Scholar]
  6. Pennebaker J. B., Gilliam J. N., Ziff M. Immunoglobulin classes of DNA binding activity in serum and skin in systemic lupus erythematosus. J Clin Invest. 1977 Dec;60(6):1331–1338. doi: 10.1172/JCI108892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Santos G. W., Owens A. H., Jr 19S and 17S antibody production in the cyclophosphamide- or methotrexate-treated rat. Nature. 1966 Feb 5;209(5023):622–624. doi: 10.1038/209622a0. [DOI] [PubMed] [Google Scholar]
  8. Shiraki M., Fujiwara M., Tomura S. Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis. Clin Exp Immunol. 1984 Feb;55(2):333–339. [PMC free article] [PubMed] [Google Scholar]
  9. Steward M. W., Hay F. C. Changes in immunoglobulin class and subclass of anti-DNA antibodies with increasing age in N/ZBW F1 hybrid mice. Clin Exp Immunol. 1976 Nov;26(2):363–370. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES